ALISKIREN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Aliskiren, and when can generic versions of Aliskiren launch?
Aliskiren is a drug marketed by Ph Health and is included in one NDA.
The generic ingredient in ALISKIREN is aliskiren hemifumarate. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the aliskiren hemifumarate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Aliskiren
A generic version of ALISKIREN was approved as aliskiren hemifumarate by PH HEALTH on March 22nd, 2019.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ALISKIREN?
- What are the global sales for ALISKIREN?
- What is Average Wholesale Price for ALISKIREN?
Summary for ALISKIREN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for ALISKIREN |
| What excipients (inactive ingredients) are in ALISKIREN? | ALISKIREN excipients list |
| DailyMed Link: | ALISKIREN at DailyMed |
US Patents and Regulatory Information for ALISKIREN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ph Health | ALISKIREN HEMIFUMARATE | aliskiren hemifumarate | TABLET;ORAL | 206665-001 | Mar 22, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Ph Health | ALISKIREN HEMIFUMARATE | aliskiren hemifumarate | TABLET;ORAL | 206665-002 | Mar 22, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
